Apatinib (a small‐molecule TKI that blocks VEGFR/PDGFR/c‐Kit/RET/Src) has also been reported to enhance the antitumor activity of EGFR–TKI in NSCLC with acquired resistance.12 This evidence concerns the gene EGFR and non-small cell lung carcinoma.